Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 10/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | JAK3 | P52333 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898303 | 1.00 | PDPK1 (1.00) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL1162656 | 1.00 | PDPK1 (1.00) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL30898301 | 1.00 | PDPK1 (1.00) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL29385385 | 1.00 | PDPK1 (1.00) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL13038796 | 1.00 | PDPK1 (1.00) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL32676559 | 0.85 | PDPK1 (0.74) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL32676535 | 0.85 | PDPK1 (0.74) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL32676572 | 0.85 | PDPK1 (0.74) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL7819649 | 0.82 | PDPK1 (0.68) | PDPK1TLK2PDGFRBKDRRET | |
| SCHEMBL7819646 | 0.82 | PDPK1 (0.68) | PDPK1TLK2PDGFRBKDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641435-A2 | RATE CONTROLLED RELEASE OF A PHARMACEUTICAL AGENT IN A BIODEGRADABLE DEVICE | BAUSCH & LOMB INCORPORATED (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050031669-A1 | Rate controlled release of a pharmaceutical agent in a biodegradable device | BAUSCH & LOMB INCORPORATED (US) | 2005-02-10 | — | — | US | claimed |
| WO-2004112748-A2 | RATE CONTROLLED RELEASE OF A PHARMACEUTICAL AGENT IN A BIODEGRADABLE DEVICE | BAUSCH & LOMB INCORPORATED (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040253293-A1 | Rate controlled release of a pharmaceutical agent in a biodegradable device | BAUSCH & LOMB INCORPORATED | 2004-12-16 | — | — | US | claimed |
| EP-0769947-B1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 2001-05-02 | — | — | EP | claimed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | claimed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | claimed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | claimed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-2635568-B1 | PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECH CO LTD (CN) | 2017-08-16 | — | — | EP | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5880141-A | CONTROLLING, MODULATING AND INHIBITING TYROSINE KINASE SIGNAL TRANSDUCTION | SUGEN, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | CSF1R, CSF3R, CD209 | PDPK1 3443/4885TLK2 4160/4885PDGFRB 31/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | PDPK1 58/4885TLK2 1011/4885PDGFRB 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.